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Abstract
Aims: The aim of this study was to investigate the predictors of long-term adverse clinical events after 
implantation of the everolimus-eluting Absorb bioresorbable vascular scaffold (BVS).
Methods and results: We pooled patient-level databases derived from the large-scale ABSORB 
EXTEND study and five high-volume international centres. Between November 2011 and November 2015, 
1,933 patients underwent PCI with a total of 2,372 Absorb BVS implanted. The median age was 61.0 (IQR 
53.0 to 68.6) years, 24% had diabetes, and 68.2% presented with stable coronary artery disease. At a median 
follow-up of 616 days, MACE occurred in 93 (4.9%) patients, all-cause death in 36 (1.9%) patients, myo-
cardial infarction in 47 (2.5%) patients, and target vessel revascularisation in 72 (3.8%) patients. Definite or 
probable scaffold thrombosis occurred in 26 (1.3%) patients. On multivariable logistic regression analysis, 
acute coronary syndromes (hazard ratio [HR] 2.79, 95% confidence interval [CI]: 1.47 to 5.29; p=0.002), 
dyslipidaemia (HR 1.43, 95% CI: 1.23 to 1.79; p=0.007), scaffold/reference diameter ratio >1.25 (HR 1.49, 
95% CI: 1.18 to 1.88; p=0.001), and residual stenosis >15% (HR 1.67, 95% CI: 1.34 to 2.07; p<0.001) were 
independent predictors of MACE, whereas the use of intravascular imaging was independently associated 
with a reduction in MACE (HR 0.13, 95% CI: 0.06 to 0.28; p<0.001).
Conclusions: Optimal Absorb BVS implantation and the use of intravascular imaging guidance are assoc-
iated with lower rates of adverse events at long-term follow-up.
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Abbreviations
BVS bioresorbable vascular scaffold(s)
DES drug-eluting stent(s)
EES everolimus-eluting metallic stent
MACE major adverse cardiac events
MI myocardial infarction
PCI percutaneous coronary intervention
PSP predilation, sizing, and post-dilation
Introduction
Over the past few decades, drug-eluting stents (DES) have 
become the gold standard for the treatment of coronary artery 
disease; however, the permanent metallic structure and polymer 
left within the coronary artery wall have been associated with 
incomplete endothelialisation, chronic inflammation, toxicity, 
loss of normal vessel curvature, impaired vasomotion, stent frac-
ture, and neoatherosclerosis1. This could lead to a long-term risk 
of adverse events including myocardial infarction (MI), target 
lesion revascularisation, stent thrombosis, and death at a rate of 
approximately 2.5% annually2. As a result, fully bioresorbable 
vascular scaffolds (BVS) have emerged as a promising alterna-
tive to metallic DES, with the goal of achieving better long-term 
results3.
Since the introduction of the everolimus-eluting Absorb™ 
BVS (Abbott Vascular, Santa Clara, CA, USA) in 2011, over 
150,000 procedures in more than 100 countries have been per-
formed using the device (data on file at Abbott Vascular as of 
April 2017). Recent studies have raised safety concerns about 
the Absorb, specifically regarding higher rates of device throm-
bosis compared with DES4-7. Of note, scaffold thrombosis has 
been reported to occur relatively early (within 30 days), suggest-
ing that implantation technique rather than delayed healing may 
play a major role. Absorb is a balloon-expandable bioresorbable 
poly-L-lactide scaffold that has relatively thick struts (157 μm 
versus 70-80 μm in metallic DES); an appropriate implantation 
technique including predilation, sizing, and post-dilation (PSP) 
has been recommended for optimal device implantation6,8,9. The 
importance of vessel size selection comes from the ABSORB 
III trial5,6, in which the overall rate of scaffold thrombosis was 
twofold higher in patients treated with the Absorb BVS com-
pared with those receiving an everolimus-eluting metallic stent 
(EES). When small (<2.25 mm) vessels were excluded, the 
rate of device thrombosis was similar between groups. In addi-
tion, when optimal/PSP technique for BVS implantation was 
performed, rates of target lesion failure and scaffold thrombo-
sis were similar with Absorb compared with EES. Hence, pro-
cedure-related factors such as lesion selection and preparation, 
vessel sizing, and scaffold post-implantation dilation seem to 
be of paramount importance for Absorb implantation. In a post 
hoc analysis, we sought to investigate the predictors of adverse 
events at long-term follow-up from a pooled patient-level data-
base of the large-scale ABSORB EXTEND study and high-vol-
ume international centres.
Methods
We pooled patient-level databases derived from the ABSORB 
EXTEND (n=812 from January 2010 to October 2013) study and 
five high-volume international centres (Hospital Israelita Albert 
Einstein, São Paulo, Brazil [n=120 from November 2014 to June 
2015]; San Raffaele Scientific Institute, Milan, Italy [n=223 
from May 2013 to May 2015]; Ferrarotto Hospital, University 
of Catania, Catania, Italy [n=392 from March 2013 to June 
2014]; Thoraxcenter, Erasmus Medical Center, Rotterdam, the 
Netherlands [n=356 from September 2012 to December 2015]; 
Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil [n=30 
from January 2015 to June 2015]). Between November 2011 and 
November 2015, 1,933 patients underwent percutaneous coronary 
intervention (PCI) with a total of 2,372 Absorb BVS implanted. 
ABSORB EXTEND (N=812) was a global registry with a goal 
of expanding experience with the Absorb BVS system to different 
geographies with broader inclusion criteria in order to include the 
treatment of longer lesions and multiple vessels10. The five high-
volume international centres (N=1,121) involved in the post hoc 
analysis included unselected “real-world” patients treated with the 
Absorb BVS. The choice of Absorb implantation in each centre 
was based on operator discretion and device availability, not on 
any specific institutional protocol. Intravascular imaging (optical 
coherence tomography [OCT] or intravascular ultrasound [IVUS]) 
was performed at the discretion of the operator at each participat-
ing centre.
DEFINITIONS
Reference vessel diameter, lesion length, and in-scaffold percent 
stenosis were assessed by online quantitative coronary angio-
graphy and were captured from the ABSORB EXTEND study 
data set and each individual centre. “Absorb oversize” was defined 
as when the vessel diameter was smaller than the nominal size of 
the implanted scaffold (scaffold/reference vessel ratio >1).
We assessed 30-day and long-term rates of all-cause death, 
MI, major adverse cardiac events (MACE - a combination of 
death, target vessel MI, or clinically driven target vessel revas-
cularisation), and definite/probable scaffold thrombosis. Scaffold 
thrombosis was classified according to the Academic Research 
Consortium definition as definite or probable11. Q-wave MI was 
the development of a new, pathological Q-wave. Non-Q-wave 
??????????????????????????????????????????????????????????????????
the upper limit of normal with elevated CK-MB in the absence 
of new pathological Q-waves. Ischaemia-driven target lesion 
revascularisation was defined as any repeat percutaneous inter-
vention or bypass surgery.
STATISTICAL ANALYSIS
Discrete data were summarised as percent (frequencies) and com-
??????????2 analysis or Fisher’s exact test. Continuous data were 
expressed as mean±standard deviation or median and interquar-
tile range based on their distribution and compared using the 
Wilcoxon rank-sum test. Time-to-event variables are presented 
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as Kaplan-Meier estimates and compared using the log-rank test 
at a median follow-up of 616 days. Multivariable analyses were 
conducted with a Cox regression model for the occurrence of 
MACE, using all variables shown in Table 1 and Table 2. The 
?????????????????????????????????????? ??? ??????????????? ???????????
analyses was included in the multivariable regression analyses. 
After discarding variables that showed collinearity, multivariable 
models were created using a selection of clinically and procedur-
ally relevant variables in order to avoid overfitting. The follow-
ing covariates were selected for inclusion in the Cox analysis: 
clinical – female sex, age, family history of premature coronary 
artery disease, hypertension, diabetes, dyslipidaemia, prior MI, 
prior PCI, creatinine clearance, and acute coronary syndromes; 
procedural – reference vessel diameter, scaffold diameter, intra-
vascular imaging utilisation, post-dilatation pressure, scaffold/ref-
erence diameter ratio >1.25, and post-procedure stenosis >15%. 
Forward selection was used, and the entry and stay criteria were 
set to 0.05. Receiver operating characteristic (ROC) curves were 
constructed to assess the predictive accuracy of the scaffold over-
size and final residual stenosis for 30-day and long-term adverse 
events. The minimum absolute value of sensitivity-specificity for 
these variables was chosen as the optimal ROC cut-off point. The 
pattern of missing data shown was arbitrary. Missing data were 
then approached using multiple imputation with regression model 
analysis; this was carried out five times. The highest percentage of 
missing data was 8%. Follow-up of the patients was censored in 
April 2014 for ABSORB EXTEND and in November 2015 or at 
the last known event-free time point (whichever came first) for the 
other sites. All statistical tests were two-tailed. Statistical signifi-
cance was set at a level of 0.05. SPSS, Version 21.0 (IBM Corp., 
Armonk, NY, USA) was used for all statistical analyses.
Results
PATIENTS, PROCEDURES, AND ADVERSE EVENTS
The median age was 61.0 years (interquartile range 53.0 to 68.6), 
24% had diabetes, 68.2% presented with stable coronary artery 
disease, and 67.9% had single-vessel coronary artery disease 
(Table 1). As shown in Table 2, 97% of the lesions were de novo, 
19.3% were bifurcations, and 18.1% had severe calcification. The 
median total length of the implanted scaffold was 18.0 mm (inter-
quartile range 18.0-28.0), scaffolds overlapped in 22.3% of cases, 
post-dilatation was performed in 75.6%, and a final Thrombolysis 
In Myocardial Infarction (TIMI) 3 flow was attained in 98.7%. 
Compared with patients without MACE, those with MACE were 
more often women, more frequently non-smokers, and had higher 
rates of prior MI, prior PCI, American College of Cardiology 
(ACC)/American Heart Association (AHA) class B2 lesions, ref-
erence diameter <2.5 mm, smaller scaffold diameter, scaffold/ref-
erence diameter ratio >1.25, and post-procedure stenosis >15%.
At a median follow-up of 616 days, MACE occurred in 93 
(4.9%) patients, all-cause death in 36 (1.9%) patients, MI in 47 
(2.5%) patients, and target vessel revascularisation in 72 (3.8%) 
patients. Definite or probable scaffold thrombosis occurred in 26 
(1.3%) patients (Figure 1, Table 3).
Table 1. Patient baseline clinical characteristics according to the occurrence of MACE.
Overall (n=1,933) No MACE (n=1,896) MACE (n=37) p-value
Age, years 61.0 (53.0-68.6) 61.4 (53.1-69.0) 64.5 (56.6-70.5) 0.16
Male 1,526 (78.9%) 1,504 (79.3%) 22 (59.5%) 0.007
Body mass index 26.8 (24.4-29.6) 26.8 (24.4-29.7) 26.6 (23.6-29.5) 0.74
Current smoker 459 (23.7%) 454 (23.9%) 5 (13.5%) 0.10
Hypertension 1,273 (65.9%) 1,244 (65.6%) 29 (78.4%) 0.12
Diabetes 463 (24.0%) 451 (23.8%) 12 (32.4%) 0.24
Insulin-requiring 108 (5.6%) 105 (5.5%) 3 (8.1%) 0.46
Dyslipidaemia 1,201 (62.1%) 1,172 (61.8%) 29 (78.4%) 0.06
Previous myocardial infarction 368 (19%) 352 (18.6%) 16 (43.2%) 0.001
Previous PCI 523 (27.1%) 507 (26.7%) 16 (43.2%) 0.04
Previous CABG 48 (2.5%) 48 (2.5%) 0 (0.0%) 1.00
Number of 
diseased 
vessels
1 1,312 (67.9%) 1,289 (68.0%) 23 (62.2%)
0.292 458 (23.7%) 447 (23.6%) 11 (29.7%)
3 163 (8.4%) 160 (8.4%) 3 (8.1%)
Clinical 
presenta-
tion
Stable coronary artery disease 1,168 (60.4%) 1,141 (60.2%) 27 (73.0%) 0.09
Unstable angina 391 (20.2%) 384 (20.3%) 7 (18.9%) 1.00
Non-STEMI 208 (10.7%) 206 (10.9%) 2 (5.4%) 0.73
STEMI 166 (8.6%) 165 (8.7%) 1 (2.7%) 0.52
Values are median (interquartile range) or n (%). CABG: coronary artery bypass graft; MACE: major adverse cardiac events; PCI: percutaneous coronary 
intervention; STEMI: ST-elevation myocardial infarction
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PREDICTORS OF MACE
Using multivariable logistic regression analysis, female sex, prior 
PCI, prior MI, scaffold/reference diameter ratio >1.25, residual 
stenosis >15%, and reference diameter <2.5 mm were independ-
ent predictors of MACE at 30 days (Table 4). Acute coronary 
syndromes, dyslipidaemia, scaffold/reference diameter ratio 
>1.25, and residual stenosis >15% were independent predictors 
of MACE, whereas intravascular imaging utilisation was assoc-
iated with a reduction in MACE at long-term follow-up. As shown 
in Figure 2, optimal Absorb BVS implantation as assessed by 
angiography (i.e., scaffold/mean reference diameter ratio <1.25 
and residual stenosis <15%) and intravascular imaging guidance 
(IVUS or OCT) were associated with lower MACE at long-term 
follow-up.
Table 2. Lesion and procedural characteristics according to the occurrence of MACE.
Overall (n=2,372) No MACE (n=2,280) MACE (n=92) p-value
De novo lesion 97.0 97.0 96.7 0.76
Lesion complexity A 6.5 7.0 1.1
0.007
B1 38.8 40.4 31.8
B2 37.3 37.9 54.5
C 14.1 14.7 12.5
Pre-procedure TIMI 
flow
0 7.2 7.2 8.4
0.15
1 1.5 1.6 0.0
2 8.1 8.3 2.4
3 83.2 82.9 89.2
Bifurcation 19.3 19.1 25.0 <0.001
Severe tortuosity 1.6 2.5 3.5 0.49
Severe calcification 18.1 18.1 20.9 0.49
Angiographic thrombus 2.9 3.7 2.3 0.77
Chronic total occlusion 3.2 4.0 2.2 0.58
Diameter stenosis, % 67.0 (56.0-80.0) 67.0 (55.0-80.0) 61.5 (55.9-73.5) 0.09
Lesion length, mm 14.0 (10.0-19.5) 14.4 (10.1-22.0) 15.2 (10.0-20.1) 0.75
Proximal reference diameter, mm 2.91 (2.66-3.23) 2.92 (2.66-3.23) 2.79 (2.45-3.08) 0.02
Distal reference diameter, mm 2.60 (2.36-2.90) 2.61 (2.36-2.90) 2.48 (2.12-2.80) 0.002
Predilatation 96.9 96.9 98.9 0.52
Number of scaffolds 1.0 (1.0-1.0) 1.0 (1.0-1.0) 1.0 (1.0-2.0) 0.01
Concomitant metallic stent 11.9 11.8 16.7 0.33
Number of metallic stents 0.18±0.55 0.17±0.54 0.33±0.90 0.25
OCT use 16.1 17.0 8.8 0.19
IVUS use 14.9 13.7 2.8 0.05
Any overlap 22.3 30.5 32.4 0.72
Scaffold total length, mm 18.0 (18.0-28.0) 21.8 (18.0-30.0) 18.0 (18.0-32.0) 0.36
Scaffold diameter, mm 3.0 (3.0-3.25) 3.0 (3.0-3.25) 3.0 (3.0-3.0) 0.04
Implantation pressure, atm 12.5±3.2 12.7±3.2 13.2±2.6 0.33
Post-dilation 75.6 75.4 83.2 0.50
Post-dilation balloon diameter, mm 3.2±0.4 3.2±0.4 3.1±0.4 0.02
Post-dilatation pressure, atm 17.7±0.4 17.5±3.7 16.0±2.6 0.05
Final device/reference ratio 1.10 (1.01-1.23) 1.08 (0.99-1.20) 1.14 (1.0-1.27) 0.06
TIMI flow post 
procedure
0 0.1 0.1 0.0
0.93
1 0.1 0.04 0.0
2 1.1 1.1 1.1
3 98.7 98.8 98.9
Final diameter stenosis 13.0 (7.0-18.0) 13.0 (8.0-18.0) 17.8 (13.6-21.8) <0.001
Values are %, median (interquartile range), or mean±standard deviation. MACE: major adverse cardiac events; TIMI: Thrombolysis In Myocardial Infarction
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Figure 1. Kaplan-Meier curves for adverse events at 616 days. MACE: major adverse cardiac events; MI: myocardial infarction; ST: scaffold 
thrombosis; TLR: target lesion revascularisation; TVR: target vessel revascularisation
Table 3. Thirty-day and 1.7-year cumulative MACE in the overall 
population (1,933 patients).
30 days
MACE 37 (1.9%)
All-cause death 5 (0.4%)
Myocardial infarction 34 (1.8%)
Target vessel revascularisation 8 (0.4%)
Target lesion revascularisation 8 (0.4%)
Definite/probable scaffold thrombosis 13 (0.7%)
1.7 years
MACE 93 (4.9%)
All-cause death 36 (1.9%)
Myocardial infarction 47 (2.5%)
Target vessel revascularisation 72 (3.8%)
Target lesion revascularisation 72 (3.8%)
Definite/probable scaffold thrombosis 26 (1.3%)
Values are n (%). MACE: major adverse cardiac events
Table 4. Independent clinical and angiographic predictors of MACE.
Hazard ratio (95% 
confidence interval) p-value
30 days
Female 3.60 (2.68-4.82) <0.001
Prior PCI 1.49 (1.07-1.95) 0.01
Prior myocardial infarction 3.05 (2.27-4.09) <0.001
Scaffold/reference ratio >1.25 2.48 (1.19-5.18) 0.01
Residual stenosis >15% 2.60 (1.20-5.65) 0.01
1.7 years
Acute coronary syndrome 2.79 (1.47-5.29) 0.002
Dyslipidaemia 1.43 (1.23-1.79) 0.007
Scaffold/reference ratio >1.25 1.49 (1.18-1.88) 0.001
Residual stenosis >15% 1.67 (1.34-2.07) <0.001
Intravascular imaging use 0.13 (0.06-0.28) <0.001
Scaffold/reference ratio and reference vessel diameter <2.5 mm were 
variables in the regression models. In the 2 models scaffold/reference 
ratio surpasses the importance of the small vessel diameter as a 
predictor of MACE. MACE: major adverse cardiac events
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Discussion
The main findings of the present study, which includes mostly 
“real-world” Absorb BVS implantation, can be summarised as fol-
lows: 1) in high-volume centres with established experience with 
the Absorb BVS there was a relatively low rate of MACE and 
scaffold thrombosis; 2) female sex, prior PCI, prior MI, a high 
ratio between scaffold and reference vessel diameter, and residual 
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Figure 2. Kaplan-Meier curves for adverse events at 630 days 
according to the angiographic optimal criteria of Absorb BVS 
implantation and intravascular imaging use. Patients with optimal 
device implantation (scaffold/mean reference diameter ratio <1.25 
and residual stenosis <15%) and intravascular imaging guidance 
had a significant reduction in major adverse cardiac events (MACE).
stenosis were independently correlated with clinical events at 
30 days; 3) acute coronary syndromes, dyslipidaemia, a high ratio 
between scaffold and reference diameter, and residual stenosis 
were independently correlated with clinical events at long-term 
follow-up. Intravascular imaging guidance was also associated 
with a significant reduction in MACE.
Absorb BVS have shown a number of potential advantages over 
DES. The absence of a rigid metallic cage may facilitate resto-
ration of vessel vasomotor tone, adaptive shear stress, and late 
luminal enlargement, and may promote a preventive effect on 
atherosclerotic plaque progression3,12,13; however, recent evidence 
has raised concerns about BVS safety, mainly due to scaffold 
thrombosis. Absorb BVS implantation has been associated with 
a twofold to fourfold higher risk of device thrombosis compared 
with EES4-7. It has been reported that the risk of this harmful event 
is higher mainly between one and 30 days after implantation5,7,14,15. 
In the present series, however, use of the Absorb BVS in patients 
with a wide range of clinical and angiographic scenarios resulted 
in MACE in 1.9% and definite/probable device thrombosis in 
0.7% at 30 days, and definite/probable device thrombosis in 1.3% 
at 1.7 years of follow-up.
The increased rate of events in the first month after implantation 
suggests that the different mechanical properties of the BVS may 
play a role in their occurrence. Polymeric BVS have about a 10 
times lower tensile strength and six times lower elongation com-
pared to DES16. Previous smaller studies have shown that Absorb 
BVS oversize and implantation in small (diameter <2.5 mm) ves-
sels are associated with adverse clinical events8,17. Conversely, the 
current analysis showed that device–vessel mismatch, as assessed 
by angiography, surpasses the importance of small vessel diameter. 
Indeed, while implantation in vessels <2.5 mm was only a uni-
variate predictor, a scaffold/reference diameter ratio >1.25 was an 
independent predictor of 30-day MACE. As the smallest available 
diameter of the Absorb BVS is 2.5 mm, its implantation in vessels 
<2.5 mm should be considered a device–vessel mismatch. Of note, 
previous studies classified device mismatch when the proximal or 
distal maximal lumen diameter was larger than the implanted scaf-
fold17. In the present analysis, we assessed the ratio between device 
size and the mean (proximal and distal) reference diameter.
Another key factor connected with clinical events in our study 
was the presence of residual stenosis. This may be due to subop-
timal scaffold expansion that may lead to a denser polymer sur-
face pattern, flow disturbances, and microthrombus formation17,18. 
Considering that this polymeric device has a reduced mechanical 
strength in vivo compared to a metallic DES, our data emphasise 
the importance of diminishing the diameter stenosis as much as 
possible before Absorb BVS implantation. Although bench test 
results suggest comparable radial force for Absorb BVS and the 
metallic XIENCE DES (Abbott Vascular), quantitative coronary 
angiography analyses5,19,20 have demonstrated less acute gain, 
a smaller minimum lumen diameter, and greater residual stenosis 
after Absorb BVS implantation, most likely reflecting greater acute 
recoil. Appropriate vessel selection (>2.5 mm by visual estimation) 
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and meticulous lesion preparation prior to Absorb BVS implanta-
tion, along with high-pressure balloon post-dilatation, have been 
strongly recommended to obtain optimal results and reduce MACE. 
A recent report8 has shown that, when an optimal Absorb BVS-
specific implantation strategy was implemented in a “real-world” 
population, scaffold thrombosis rates fell from 3.3% to 1.0% at one 
year. Likewise, in the ABSORB III trial6 when the PSP protocol 
was used for scaffold implantation (predilation at a 1:1 balloon-to-
artery ratio with a non-compliant balloon that has been sized appro-
priately and routine post-dilation – up to 0.5 mm larger than the 
nominal scaffold diameter), better clinical outcomes were achieved.
In our analysis, intravascular imaging use (OCT or IVUS com-
pared with angiography alone) was associated with a reduction in 
clinical events at long-term follow-up. Intravascular imaging guid-
ance during Absorb BVS implantation has the potential to reduce 
both scaffold thrombosis and the need for repeat revascularisa-
tion. Appropriate vessel sizing and optimal scaffold expansion 
and apposition by imaging-guided PCI may explain its association 
with a lower event rate; however, the use of additional imaging 
modalities in this pooled database (~30% of the cases) was left to 
operator discretion and was probably employed in patients with 
selected lesion/procedural characteristics. A dedicated randomised 
comparison on this matter should be explored in future studies.
Among several clinical, lesion, or procedure-related predictors 
of ST, early discontinuation of dual antiplatelet therapy (DAPT) is 
the most important factor for DES-associated late thrombosis. In 
a recent analysis by Felix at al21, DAPT discontinuation (between six 
and 18 months) following Absorb BVS implantation was potentially 
associated with scaffold thrombosis. This is one of the weaknesses 
of the present analysis, since information about DAPT compli-
ance and the type of P2Y12 used was not systematically collected.
Limitations
First, this is a post hoc analysis from multiple registries. Thus, 
the results of this study should be considered hypothesis-gener-
ating. Second, more than one third of the entire study population 
was from ABSORB EXTEND, a trial that included patients with 
lesion complexity considered at low-to-moderate risk for PCI. 
Therefore, our findings may be not representative of a truly “real-
world” population. Threats to the external validity of the present 
analysis involve the interaction of the Absorb BVS with the spe-
cific types of patients included (low-to-moderate versus high-risk 
patients), the specific clinical setting (stable versus acute coronary 
syndromes), and the date when the patients were treated (earlier 
versus after more contemporary techniques of scaffold implanta-
tion were introduced). Third, event adjudication was conducted by 
individual study sites except for the ABSORB EXTEND, which 
had a dedicated clinical events committee. This may have caused 
variability in event definitions. Each participating centre did, how-
ever, apply the Academic Research Consortium definition of stent 
thrombosis11. Fourth, information about DAPT compliance and 
the type of P2Y12 used (i.e., clopidogrel, prasugrel, or ticagre-
lor) was not specifically collected in our analysis. Fifth, there is 
no information about Absorb BVS penetration in each individual 
centre or about patient and lesion selection. Finally, although we 
adjusted for measured imbalances, we cannot completely rule out 
the possibility that not all multivariable correlates of MACE were 
identified. In addition, although multivariable models were created 
using a selection of relevant variables in order to avoid overfitting, 
the event per variable in the present analysis was less than recom-
mended and thus the results should be interpreted with caution.
Conclusions
In this pooled analysis from a large-scale patient-level population, 
Absorb BVS implantation was associated with favourable clinical 
outcomes during both short- and long-term follow-up. Patient-related 
factors predicting the risk of MACE were comparable to those pre-
viously reported for metallic DES. Optimal Absorb BVS implanta-
tion and the use of intravascular imaging guidance are associated 
with lower rates of adverse events at long-term follow-up.
Impact on daily practice
The present study identified the clinical and procedural pre-
dictors of adverse events after Absorb BVS implantation. The 
analysis showed that device–vessel mismatch assessed by 
angiography surpasses the importance of small vessel diameter. 
A scaffold/reference diameter ratio >1.25 along with residual 
stenosis >15% and non-use of intravascular imaging guidance 
were independent predictors of MACE at long-term follow-up.
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